Chuan-Yuan Wei,Meng-Xuan Zhu,Peng-Fei Zhang,Xiao-Yong Huang,Jin-Kai Wan,Xiu-Zhong Yao,Ze-Tao Hu,Xiao-Qiang Chai,Rui Peng,Xuan Yang,Chao Gao,Jian Gao,Si-Wei Wang,Yi-Min Zheng,Zheng Tang,Qiang Gao,Jian Zhou,Jia-Bin Cai,Ai-Wu Ke,Jia Fan

Abstract:PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinomaJournal of HepatologyVol. 77Issue 1PreviewDespite remarkable advances in treatment, most patients with hepatocellular carcinoma (HCC) respond poorly to anti-programmed cell death 1 (anti-PD1) therapy. A deeper insight into the tolerance mechanism of HCC against this therapy is urgently needed. Full-Text PDF Open Access It has come to our attention that there are errors in the author list and Fig. 2C,D of our manuscript. In the author list, the name of the co-corresponding author ‘Jia-Bin Cai’ was misspelled ‘Jia-Bin Fan’. Please note that ‘Jia-Bin Cai’ is the correct spelling. In Fig. 2C,D, the occurrences of ‘ZPF6’ and ‘ZF1P6’ are typos and should all read ‘ZFP64’. A corrected version of Fig.2 is included below. We apologize for any inconvenience caused.

Correction To: Predictive Biomarkers and Mechanisms Underlying Resistance to PD1/PD-L1 Blockade Cancer Immunotherapy.

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

Correction to: Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway (Journal of Experimental and Clinical Cancer Research (2018) 37 (53) DOI: 10.1186/s13046-018-0703-9)

Corrigendum To: "pkcα/zfp64/csf1 Axis Resets the Tumor Microenvironment and Fuels Anti-Pd1 Resistance in Hepatocellular Carcinoma" [J Hepatol 77 (2022) 163-176].

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

Corrigendum: Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer

Correction To: A Reactive Oxygen Species Scoring System Predicts Cisplatin Sensitivity and Prognosis in Ovarian Cancer Patients

Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Erratum to "Characterization of a predictive signature for tumor microenvironment and immunotherapy response in hepatocellular carcinoma involving neutrophil extracellular traps" [Heliyon Volume 10, issue 10, May 2024, article e30827]

Correction To: Novel Smac Mimetic APG-1387 Elicits Ovarian Cancer Cell Killing Through TNF-alpha, Ripoptosome and Autophagy Mediated Cell Death Pathway

Corrigendum: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma

Correction To: the Effects and Mechanisms of SLC34A2 in Tumorigenesis and Progression of Human Non-Small Cell Lung Cancer

Corrigendum: Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma

Corrigendum to “Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation” [EBioMedicine 41 (2019) 357–369]

Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Corrigendum to ‘Mir-873/Pd-l1 Axis Regulates the Stemness of Breast Cancer Cells’ EBioMedicine 41 (2019) 395–407